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Abstract
Aims
To quantify the extent of squamous metaplasia in bronchial biopsies and relate it to the
presence of chronic obstructive pulmonary disease (COPD), a smoking-related pathology.
Methods
Bronchial biopsies (n = 15 in each group) from smokers with COPD GOLD stage1 and
GOLD stage2, smokers without COPD and healthy non-smokers were stained immunohis-
tochemically with a panel of antibodies that facilitated the identification of pseudostratified
epithelium and distinction of squamous metaplasia and squamous epithelium from tangen-
tially cut epithelium. The percentage length of each of these epithelial phenotypes was mea-
sured as a percent of total epithelial length using computerised image analysis. Sections
were also stained for carcinoembryonic antigen and p53, early markers of carcinogenesis,
and Ki67, and the percentage epithelial expression measured.
Results
The extent of squamous metaplasia was significantly increased in both COPD1 and
COPD2 compared to healthy smokers and healthy non-smokers. The amount of fully differ-
entiated squamous epithelium was also increased in COPD1 and COPD2 compared to
healthy non-smokers, as was the expression of carcinoembryonic antigen. These features
correlated with one other.
Conclusion
In subjects with COPD there is a loss of pseudostratified epithelium accompanied by an
increase in squamous metaplasia with transition into a fully squamous epithelium and
expression of early markers of carcinogenesis.
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Introduction
Squamous metaplasia (SQM) is a pre-neoplastic change of the bronchial epithelium observed
in the lungs in response to toxic injury induced by cigarette smoke [1–4]. It is part of a multi-
stage process [5–7] which may eventually lead to full neoplastic transformation, i.e. bronchial
carcinoma. Not all SQM lesions progress to a neoplasia, particularly if low grade and some
may regress to a normal epithelium [8–10], especially after smoking cessation [11].
Initially, during SQM quiescent basal cells within the pseudostratified epithelium re-enter
the cell cycle and become hyperproliferative. During the next stage of the process, the epithe-
lium begins to express markers of a squamous phenotype rather than those of the normal pseu-
dostratified epithelium. These include squamous epithelial cytokeratins (CK) [5,6,12–14] and
the cell adhesion molecule SQM1 [15]. Finally, when fully differentiated, having a squamous
cell morphology, cells will express involucrin, a marker of terminal differentiation [16].
A history of cigarette smoking is associated with 90% of lung cancers with 15% of lifetime
smokers developing lung cancer [17–20]. Chronic obstructive pulmonary disease (COPD) is
also associated with smoking and is an independent risk factor for developing lung cancer, the
risk being increased by up to 4.5 fold [21–26]. Between 50 and 70% of subjects with lung cancer
also have COPD [18,27]. The cause of this increased susceptibility in subjects with COPD is
unknown. Several possibilities have been suggested, including common molecular pathways
[28,29], impaired ability to clear carcinogens due to obstructive airways [30] and ongoing
chronic inflammation within the airways [27,31].
SQM is observed in the bronchial epithelium of smokers [11], but to date there have been,
to our knowledge, no studies to quantify it and relate it to the coexistence and severity of
COPD. We have previously identified a panel of antibodies, CK7, CK13 and involucrin, that
are suitable for identification and distinction of SQM and squamous epithelium in endobron-
chial biopsies, from tangentially cut epithelium [32], which is difficult based on morphology
alone in small biopsies. CK7 is seen in luminal cells of the pseudostratified epithelium and its
expression is lost during SQM and absent in squamous epithelium. CK13 expression is
restricted to the basal cells of pseudostratified epithelium but is observed throughout the epi-
thelium with SQM or a squamous phenotype. Involucrin is restricted to cells with a fully differ-
entiated squamous morphology. This staining pattern is summarised in Fig 1 in the results.
The aim of the current study was to quantitate, using the above panel of antibodies, the
amount of SQM and squamous epithelium (SE) within the bronchial epithelium of smokers
with and without COPD, compared to healthy controls. Additionally, we have looked at the
expression of the proliferation marker, Ki67, and the early markers of carcinogenesis, carcino-
embryonic antigen (CEA) and p53. The relationship to severity of COPD and smoking history
was also investigated.
Materials and Methods
Subjects and study design
This study used previously collected glycol methacrylate embedded bronchial biopsies from
four subject groups (n = 15 in each group); healthy non-smokers, healthy smokers, and COPD
subjects classified according to the GOLD guidelines [33] as having COPD stage 1 airflow
obstruction (COPD1) and COPD stage 2 airflow obstruction(COPD2). The clinical character-
istics of each subject were fully characterised (Table 1); data from some of these subjects has
been reported previously [34].
This study was approved by National Research Ethics Service Committee South Central—
Southampton B (11/SC/0103) and the original biopsy collection for which subjects gave written
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informed consent by Southampton and South West Hampshire Research Ethics Committee
(276/99 and 09/H0502/91).
Immunohistochemistry
Two-micron sections were cut and stained immunohistochemically using an avidin-biotin
technique and a panel of antibodies we have previously validated that facilitate the distinction
and identification of epithelium with squamous metaplasia and fully squamous phenotype
from tangentially cut epithelium in biopsy samples [32](Fig 1). This included mouse monoclo-
nal antibodies to cytokeratin (CK) 7, CK13 and involucrin. We also used mouse monoclonal
antibodies to pan-CKs (as a positive control), the proliferation marker Ki67 and to the early
carcinogenesis markers p53 and carcinoembryonic antigen (CEA). Negative control sections
were incubated with Tris-buffered saline (TBS) in replacement for the primary antibody. Fur-
ther antibody details are shown in Table 2.
The percentage lengths of epithelium that were either pseudostratified, were undergoing
squamous metaplasia or were fully differentiated squamous epithelium, based on the patterns
of cytokeratin and involucrin expression, were measured as a percent of total epithelial length
(excluding tangentially cut) with the assistance of computerised image analysis (Zeiss KS400,
Image Associates, Bicester, UK). The percentages of the epithelium staining for CEA as area
ratio and the percentage nuclear epithelial area expression of p53 and Ki67, based on the red/
green/blue colour composition of the DAB staining [35] within the intact epithelium, were
assessed by computerised image analysis.
Table 1. Subject characteristics.
Group Gender Age (years) FVC / FEV1 FEV1 (% predicted) Smoking history (pack years)
Healthy non-smokers 6M:9F 53.6 (8.2) 77.60 (4.88) 108.67 (12.20) zero
Healthy smokers 5M:10F 48.2 (9.5) 78.80 (5.24) 100.53 (9.37) 36.73 (13.09)
COPD 1 12M:3F 56.7 (7.5) 65.13 (4.41) 91.53 (5.93) 44.00 (15.97)
COPD 2 10M:5F 56.7 (8.2) 60.87 (7.09) 66.60 (7.53) 50.33 (12.38)
Data are means and (standard deviations)
doi:10.1371/journal.pone.0156009.t001
Table 2. Panel of antibodies used.
Antibody clone Catalogue
number
Supplier Working
concentration
CEA II-7 M7072 Dako, Ely, UK 0.2 ug/ml
CK7 OV-TL 12/30 M7018 Dako, Ely, UK 0.256 ug/ml
CK13 KS-1A3 C0791 Sigma, Poole, UK 4.94 ug/ml
Pan CK C-11, PCK-26, CY-90, KS-1-A3, M20, A53-B/
A2
C2562 Sigma, Poole, UK dilution1:4000*
Involucrin SY5 MS-126-P1 ThermoFisher Scientiﬁc, Runcorn, UK 0.5 ug/ul
Ki67 MIB-1 M7240 Dako, Ely, UK 0.102 ug/ml
P53 DO-7 NCL-L-p53-DO7 Novocastra, Leica Biosystems, Newcastle,
UK
0.875 ug/ml
* concentration unavailable
doi:10.1371/journal.pone.0156009.t002
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Statistical analysis
Non-parametric statistical tests were used to analyse the results of the immunohistochemical
analysis and data presented as medians and interquartile ranges. The Kruskall-Wallis ANOVA
test was used to test for differences between the 4 groups and, where appropriate, the Mann
Whitney U test was used for further analyses, with p<0.05 considered statistically significant.
The Spearman Rank test was used to test for correlations between immunohistochemical data
and clinical parameters.
Results
Staining with CK7, CK13 and involurin enabled us to identify normal pseudostratified epithe-
lium, that was undergoing squamous metaplasia and that had had undergone transition to a
fully squamous epithelium (Fig 1). In normal pseudostratified epithelium the columnar and
goblet cells were CK7+ and the basal cells CK13+. In squamous metaplasia CK13+ cells were
seen throughout epithelium. In fully differentiated squamous epithelium involucrin+ cells were
observed at the luminal surface (Fig 1).
Fig 1. Cytokeratin and involucrin expression in the bronchial epithelium during transition from a normal pseudostratified
epithelium to a squamous phenotype. Diagram, with matching photographs from bronchial biopsies included in this study, illustrating
how the expression of CKs and involucrin (brown) changes as the normal pseudostratified bronchial epithelium undergoes transition
towards a squamous phenotype.
doi:10.1371/journal.pone.0156009.g001
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A mean length of 2.04mm of epithelium was assessed for each subject. The extent of squa-
mous metaplasia was increased in both COPD1 and COPD2, 16.5% (0–23.4%) & 10.0%
(0–30.9%), respectively, when compared to healthy smokers (0% (0–5.2%)(p = 0.041 &
p = 0.033) and healthy non-smokers (0%(0–0%))(p = 0.015 & p = 0.004)(Fig 2A). This was
paralleled by a decrease in pseudostratified epithelium (Fig 2B). The amount of fully differenti-
ated squamous epithelium was also increased in COPD1 (7.4% (0–32.7%)) and COPD2
(6.67%(0–44.8%)) compared to healthy non-smokers (0%(0–0%)), p = 0.011 and p = 0.004,
respectively but not healthy smokers (Fig 2C).
There was a positive correlation between the extent of this squamous metaplastic and fully
differentiated squamous epithelium and a corresponding negative relationship to the amount
of pseudostratified epithelium as it is replaced by these altered phenotypes (Table 3).
Staining for CEA was observed in the luminal cells of the pseudostratified bronchial epithe-
lium (Fig 3A) and was increased in COPD1 (0.7% (0.3–2.7%)) and COPD2 (0.7%(0.1–3.0%))
compared to healthy non-smokers (0%(0–0%))(p<0.001 for both groups)(Fig 3E). P53 was
weakly expressed in the perinuclear region of cells (Fig 3B), Ki67 staining was also nuclear
Fig 2. Graphs showing epithelial phenotype. The percentage of epithelium with squamous metaplasia (A), that with a
pseudostratified (B) and a fully squamous (C) phenotype are shown in healthy non-smokers (●), healthy smokers (■) and subjects
with COPD1(▲) and COPD2(▼). Significant differences between the groups are indicated.
doi:10.1371/journal.pone.0156009.g002
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(Fig 3C). There was no difference in the expression of p53 or Ki67 across the groups (KW
p = 0.14 and p = 0.52, respectively)(Fig 3F and 3G)).
The expression of both CEA and Ki67 had a positive relationship with the amount of epithe-
lium with squamous metaplasia and that with a fully differentiated squamous phenotype and a
negative relationship with pseudostratified epithelium. There were no correlations with p53
(Table 3).
The epithelial phenotype and expression of CEA and Ki67correlated with lung function but
not with smoking history (Table 4). There was a negative relationship between squamous
metaplasia, the amount of fully squamous epithelium, CEA expression with both Forced Expi-
ratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) /FEV1 and a positive rela-
tionship between the amount of pseudostratified epithelium and lung function. Ki67 had a
negative correlation with FEV1 only.
Discussion
This study demonstrates increased expression of epithelial markers that are consistent with a
squamous metaplastic phenotype, together with a loss of normal pseudostratified epithelium,
in smokers with COPD when compared to both healthy smokers and healthy non-smokers.
Furthermore an increase in the amount of epithelium with a fully differentiated squamous phe-
notype is observed in smoking COPD patients when compared to healthy non-smokers (Figs 1
& 2). These changes are accompanied by increased expression of the early carcinogenesis
marker, CEA.
To our knowledge this is the first study assessing the extent of SQM within the bronchial
epithelium of smokers with and without COPD and healthy control participants. Cosio et al
[1] have reported increased SQM in the small airways of subjects with FVC/FEV1 ratios in the
COPD range compared to those with lung function in the normal range. Together these data
suggest that SQM can occur throughout the airways in response to cigarette exposure.
SQM has been observed to be increased in the bronchial epithelium of COPD patients who
are current smokers when compared to those who are ex-smokers [11] and to be related to the
intensity of smoking (number of cigarettes smoked in a day), but not pack year history [3]. In
our study, all of the COPD subjects were current smokers and we also did not observe any rela-
tionship with pack-year history. We found no difference in SQM between healthy non-smokers
and healthy current smokers, suggesting that COPD is a contributing factor to these SQM
changes rather than smoking alone. The correlation of SQM with both FVC/FEV1 and FEV1
may suggest that similar mechanisms are driving the loss of lung function and the development
of SQM. This is supported by the study of Araya et al [36] who linked SQM with evidence of
fibroblast activation and correlated this with small airway wall thickening in COPD and disease
severity.
In our study transition to a fully differentiated squamous epithelium, indicated by positive
staining for involucrin in epithelium with a squamous phenotype, was higher in subjects with
Table 3. Epithelial correlations.
Fully squamous epithelium Pseudostratiﬁed epithelium CEA expression Ki67 expression
SQM Epithelium Rho = 0.686 p<0.001 Rho = -0.909 p<0.001 Rho = 0.329 P = 0.010 Rho = 0.408 P = 0.001
Fully squamous epithelium na Rho = -0.885 p<0.001 Rho = 0.407 p = 0.001 Rho = 0.414 p = 0.001
Pseudostratiﬁed epithelium na na Rho = -0.423 p = 0.001 Rho = -0.468 p<0.001
Spearman’s rho
doi:10.1371/journal.pone.0156009.t003
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Fig 3. Epithelial expression of early markers of carcinogenesis and proliferation. CEA is expressed in the luminal cells of
pseudostratified epithelium (A), p53 is weakly expressed in the perinuclear region of suprabasal cells (B), nuclear expression of ki67 can
also be seen (C). Positive staining is brown. No staining was observed in the negative controls sections (D). Scale bar = 20 um. The
percentage of the epithelium expressing CEA (E), p53 (F) and Ki67 (G) are shown in healthy non-smokers (●), healthy smokers (■) and
subjects with COPD1(▲) and COPD2(▼). Significant differences and Kruskall Wallis P values between the groups are indicated.
doi:10.1371/journal.pone.0156009.g003
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COPD1 and 2 compared to healthy non-smokers but not compared to healthy smokers. This
suggests this is a consequence of both smoking and COPD. This concurs with the study by
Araya [36] in which increased intensity of involucrin staining was reported in samples
obtained during surgery for lung cancer in patients who also had stage 2 and 3 COPD, when
compared to healthy organ donor lungs.
A possible mechanism for this shift towards a squamous epithelial phenotype is via activa-
tion of the epidermal growth factor (EGF) / EGF receptor (EGFR) pathway due to the oxidative
stress induce by cigarette smoke [37]. Shakhiev et al have demonstrated that EGF in air liquid
interface cultures skews the epithelium to differentiate towards a squamous phenotype with
the expression of cytokeratin 14 and involucrin [37]. We have previously demonstrated upre-
gulation of EGFR in conjunction with goblet cell hyperplasia in these subjects, but did not
investigate the relevance to the presence of SQM [38].
We also studied the expression of CEA and p53 markers of early carcinogenesis and the
expression of the cell proliferation marker Ki67.
The expression of CEA in the bronchial epithelium was increased in subjects with COPD 1
and 2 when compared to healthy non-smokers and correlated with the extent of SQM and a
fully differentiated squamous epithelium. Previous studies have found increased CEA levels in
serum and secretions of healthy smokers and subjects with COPD compared to healthy non-
smokers [39], but no difference with COPD severity [40], suggesting raised CEA is a marker of
smoking rather than the presence of COPD. However, our data and that of Athanassiadou
[13], have demonstrated that CEA expression is related to the pre-neoplastic change of SQM,
suggesting that it could be a useful marker of this pre-neoplastic change.
We did not observe any differences in the expression of either p53 or Ki67 across our subject
groups. P53, a tumour suppressor gene, expression is not observed in normal cells [41] but is
reported to be expressed in areas of epithelium with SQM [42–44] increasing as the epithelium
becomes more dysplastic [42,43,45,46]. Ki67 is also reported to be increased in areas of SQM,
and to be of predictive value in the progression to lung cancer [44]. To our knowledge none of
our subjects had lung cancer or a history of lung cancer so the pre-neoplastic changes we have
observed may be early events in this transition process, and these markers may have yet to be
upregulated. Also, we only assessed expression in areas of epithelium with a normal pseudos-
tratified appearance we did not assess expression in areas of SQM which may have been more
appropriate. However, we did observe a significant correlation between Ki67 expression and
the extent of epithelium that had a SQM and a fully squamous phenotype. Therefore future
work assessing the expression in SQM and epithelium with a fully squamous phenotype is
warranted.
SQM is a reversible pre-neoplastic change in the epithelium [8–10]. On long-term cessation
of smoking, Lapperre et al [11] report a reduction in SQM in patients with COPD when com-
pared to current smokers with COPD. Cessation also reduces the risk of progression to lung
cancer [47, 48], as does corticosteroid therapy [49]. Hence early detection of these pre-neoplas-
tic changes is important to facilitate early intervention. This is a challenge as at this early stage
Table 4. Correlations between epithelial phenotype andmeasures of lung function.
SQM epithelium Fully squamous epithelium Pseudostratiﬁed epithelium CEA expression Ki67 expression
FVC/FEV1 rho = -0.49 p<0.001 rho = -0.44 p = 0.001 rho = 0.51 p<0.001 rho = -0.40 p = 0.001 ns
FEV1 rho = -0.42 p = 0.001 rho = -0.40 p = 0.002 rho = 0.44 p<0.001 rho = -0.45 p<0.001 Rho = -0.298 p = 0.021
Spearman’s rho
doi:10.1371/journal.pone.0156009.t004
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patients are asymptomatic, only presenting when progression to lung cancer has occurred.
Autofluorescence bronchoscopy facilitates earlier detection of pre-invasive lesions [10,50–52]
especially if used with appropriate biomarkers and histological assessment. This may be a strat-
egy for monitoring high risk patients.
In conclusion we demonstrated that there is a loss of the normal pseudostratified epithelium
in smokers with COPD together with pre-neoplastic changes evidenced by increased presence
of SQM and fully differentiated squamous epithelium, together with expression of CEA. This
may warrant aggressive smoking cessation strategies, with long-term follow up to assess regres-
sion to a normal phenotype or progression to lung cancer.
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